In addition, both CD4+ and CD8+ T-lymphocytes were increased significantly in the combination group compared with the control group (Figure 8B and Table 4), suggesting that the immunomodulatory function of Rh2 may play a role in therapeutic efficacy in CT26/luc tumor-bearing mice. This evidence concerns the gene RHAG and neoplasm.